A Double-Blinded, Randomized, Placebo-Controlled, Proof of Concept Phase 2a Study Exploring the Safety and Efficacy of IMC-1 for the Treatment of Patients With Fibromyalgia

Trial Profile

A Double-Blinded, Randomized, Placebo-Controlled, Proof of Concept Phase 2a Study Exploring the Safety and Efficacy of IMC-1 for the Treatment of Patients With Fibromyalgia

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Celecoxib/famciclovir (Primary)
  • Indications Fibromyalgia; Myofascial pain
  • Focus Therapeutic Use
  • Sponsors Innovative Med Concepts
  • Most Recent Events

    • 07 Mar 2017 According to Innovative Med Concepts media release, key top-line results of this trial are published in the Journal of Pain Research.
    • 19 Nov 2014 Primary endpoint has been met (change in pain from baseline over 16 weeks).
    • 19 Nov 2014 Results presented at the 78th American College of Rheumatology and the 49th Annual Meeting of the Association of Rheumatology and Health Professionals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top